CTRI/2020/11/028896尚未招募4 期
An Open Label, Multicentric Study to Evaluate Safety and Efficacy of Cefpodoxime Proxetil Sustained Release Tablets in the Patients Having Mild to Moderate Upper Respiratory Tract Infections
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patient of either gender aged 12 to 65 years (both inclusive)
- •2. Patient with body weight ââ?°Â¥ 40 kg
- •3. Patients who are willing to provide written informed consent/assent to participate in the study. An additional written informed consent will be taken from parent/legally acceptable representative (as applicable) in case assent is taken from patient aged ââ?°Â¥ 12 and < 18 years
- •4. DISEASE SPECIFIC INCLUSION CRITERIA:
- •A. Diagnostic criteria for pharyngitis, tonsillitis or Pharyngotonsillitis:
- •I. Patient with a diagnosis of mild to moderate upper respiratory tract infection (pharyngitis, tonsillitis or Pharyngotonsillitis) based on modified Centor score (McIsaac score) ââ?°Â¥ 3 and positive for rapid antigen test (RADT) during the screening period.
- •MacIsaac score parameters-Score
- •a) Body Temperature ââ?°Â¥ 38 oC- 1
- •b) Absence of cough- 1
- •c) Swollen, Tender anterior cervical nodes- 1
- •d) Tonsillar exudate or swelling- 1
- •e) Age 3-14- 1
- •Age 15 ââ?¬â?? 44- 0
- •45 and above- -1
- •Cumulative Score ___________
- •Patients meeting the clinical criteria for pharyngitis, tonsillitis or Pharyngotonsillitis will be included in the study irrespective of the microbiological culture and antibacterial susceptibility results.
- •Ã¯Æ?Ë? Throat swab will be obtained from all patients at the time of screening for culture and antibacterial susceptibility testing (as per standard method). The specimen should be obtained from the posterior pharynx and/or the tonsillar pillars.
- •Patients with isolate(s) resistant to study medication or those who are found culture negative can be continued in the study if they show improvement clinically. Their continuation in the study will be at the discretion of the investigator.
- •Patients with persistence or worsening in the signs and symptoms of infection after at least 3 doses of treatment with the study medication will be considered as clinical failures and will be withdrawn from the study. Their further treatment will be at the discretion of the investigator. The investigator may withdraw patient at any time during the course of the study if the same is in the best interest of the patient.
- •B. Diagnostic criteria for acute bacterial sinusitis:
- •Patient should have a history of symptoms as mentioned below for a minimum of 7 days before screening, without improvement over the 3 days immediately before screening. The symptoms MUST NOT be of more than 4 weeks duration.
- •I. Clinical Criteria:
- •a. Symptoms
- •Patient with a diagnosis of acute bacterial sinusitis based on ATLEAST TWO of the following:
- •Maxillary tooth pain
- •Facial pain
- •Frontal headache
- •Purulent nasal discharge
- •New onset fetor oris (bad breath)
- •Morning cough
- •Nasal obstruction
- •A Patient should have ATLEAST ONE of the following signs:
- •Purulent secretions from sinus ostia on examination
- •Abnormal sinus transillumination
- •Pain on palpation over sinuses
- •Facial swelling
- •Generalized sign and symptoms that are consistent with a diagnosis of acute bacterial sinusitis but are otherwise nonspecific include:
- •Fever (temperature >38Ã?ºC/ >100.4Ã?ºF)
- •II. Radiological Criteria:
- •a. Evidence of acute bacterial sinusitis o
排除标准
- •Subject will be deemed ineligible to participate in the study if he/she fulfils any of the following criteria:
- •1. DISEASE SPECIFIC EXCLUSION CRITERIA
- •1.1. Pharyngitis, Tonsillitis or Pharyngotonsillitis
- •1.1.1. Patient who is a known carrier (note) of Streptococcus pyogenes based on medical history of the patient
- •1.1.2. Patient with evidence of pseudomembranous, vesicular, ulcerous or ulceronecrotic pharyngitis
- •1.2. Acute Bacterial Sinusitis:
- •1.2.1. Patient with disease history consistent with allergic and other types of rhinitis
- •1.2.2. Patient with isolated frontal and sphenoidal disease given the different pathophysiology and etiologic pathogens
- •1.2.3. Patient with cystic fibrosis
- •1.2.4. Immunocompromised patients or patients with other medical conditions that may affect interpretation of the effect and safety of trial drug
- •1.2.5. Patient with history or current evidence of nasal polyposis
- •2. Patient with history of hypersensitivity to Cefpodoxime or other Cephalosporins, penicillin or any other Ã?²-lactam class of antibiotics or any of the excipients of the study formulation
- •3. Patient with history or current evidence of rheumatic or valvular heart disease or glomerulonephritis
- •4. Patient with evidence of infection of the deep tissues of the upper respiratory tract (e.g., epiglottitis, retropharyngeal or buccal cellulitis, or abscess of the retropharynx, tonsil, or peritonsillar area) or of the suprapharyngeal respiratory tract and its connecting structures (e.g.otitis media, or orbital/periorbital cellulitis)
- •5. Patient with concurrent symptoms suggestive of viral etiology including conjunctivitis, coryza and cough; diffuse adenopathy or rash suggestive of mononucleosis; rash or arthropathy suggestive of scarlet fever
- •6. Patient requiring hospitalization for treatment for upper respiratory tract infections
- •7. Patient requiring parenteral antimicrobial treatment for upper respiratory tract infections
- •8. Patient with any other concurrent infection that necessitates the use of additional systemic antimicrobial therapy.
- •9. Patient who had received antibiotic treatment for > 24 hours during the 72 hours prior to enrollment in the study (unless treatment failure was documented)
- •10. Patient with malabsorption syndrome or other gastrointestinal disease that could affect absorption of oral study medication
- •11. Patient with history of neoplasia or immunosuppression or on chronic immunosuppressive therapy.
- •12. Patient with history of HIV, Hepatitis B and HCV
- •13. Patient who is receiving concurrent treatment with diuretics, anticoagulants and corticosteroids
- •14. Patient with history of allergies e.g., hives, rashes etc.
- •15. Patient with significant disease(s) or disorder(s) other than the disease in consideration that in the opinion of the investigator may
- •15.1. put the patient at risk because of participation in the study or
- •15.2. interfere with the study evaluations or
- •15.3. cause concern regarding patientââ?¬•s ability to participate in the study
- •16. Pregnant women or breast feeding women
- •17. Patient with history of substance abuse as per Diagnostic and Statistical Manual (DSM-5) criteria
- •18. Patient with creatinine clearance of < 30 mL/min or requirement of peritoneal or hemodialysis
研究者
相似试验
进行中（未招募）
1 期
Safety, Tolerability and Efficacy of Ceftaroline in Babies with Late-Onset Sepsisate-onset SepsisMedDRA version: 17.1Level: HLTClassification code 10040054Term: Sepsis, bacteraemia, viraemia and fungaemia NECSystem Organ Class: 100000004862EUCTR2014-003243-34-ESAstraZeneca AB24
进行中（未招募）
1 期
Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and efficacy of Ceftaroline in Neonates and Young Infants with Late-Onset SepsisEUCTR2014-003243-34-ITASTRAZENECA AB11
进行中（未招募）
1 期
Safety, Tolerability and Efficacy of Ceftaroline in Babies with Late-Onset SepsisEUCTR2014-003243-34-LTPfizer Inc.24
进行中（未招募）
1 期
Safety, Tolerability and Efficacy of Ceftaroline in Babies with Late-Onset Sepsisate-onset SepsisMedDRA version: 20.0Level: HLTClassification code 10040054Term: Sepsis, bacteraemia, viraemia and fungaemia NECSystem Organ Class: 100000005053EUCTR2014-003243-34-HUPfizer Inc.24
招募中
1 期
A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radiprodil in Patients with Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) Type IITuberous Sclerosis Complex (TSC), Focal Cortical Dysplasia (FCD) Type IIMedDRA version: 20.0Level: LLTClassification code: 10070672Term: Focal cortical dysplasia Class: 10010331MedDRA version: 21.0Level: PTClassification code: 10080584Term: Tuberous sclerosis complex Class: 100000004850CTIS2023-506301-20-00Grin Therapeutics Inc.34